Vergleich mehrerer Laborproben (Symbolbild).
Mittwoch, 24.05.2023 07:03 von | Aufrufe: 71

Biopharma Leaders Connect at Veeva R&D and Quality Summit to Advance Innovation for the Industry and Patients

Vergleich mehrerer Laborproben (Symbolbild). pixabay.com

PR Newswire

Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, Syneos Health and more share learnings on driving efficiency across the product development lifecycle

BARCELONA, Spain, May 24, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, and Syneos Health are among the speakers at Veeva R&D and Quality Summit, June 6-7 in Madrid, Spain. Industry innovators will share how they leverage next-generation solutions to drive efficiencies that help deliver better patient outcomes.

Veeva Systems

Veeva R&D and Quality Summit will bring together more than 750 industry professionals to participate in over 40 sessions. Attendees will learn about strategies for developing the foundation for clinical operations and data in patient-centric trials, elevating quality management beyond compliance, streamlining regulatory processes, and improving oversight and efficiency in safety.

Featured keynotes and panel discussions include:

  • Bayer outlining its regulatory journey to deliver a comprehensive view of approved content for a large and varied product portfolio.
  • Boehringer Ingelheim highlighting its launch of a product development operating system for the future.
  • LEO Pharma discussing the elevated role of safety as a strategic partner in product development.
  • GSK, Recordati, and Syneos Health sharing their respective journeys to improve clinical trials.

"Our top priority is helping the industry deliver innovation that ensures the best possible outcomes for patients," says Rik Van Mol, senior vice president of Veeva Development Cloud. "Veeva R&D and Quality Summit offers industry leaders an ideal forum to connect, exchange ideas, and share strategies that will drive the industry forward."

The event is open exclusively to life sciences professionals. Register and stay up to date on the agenda and program details at veeva.com/eu/Summit.

Additional Information


ARIVA.DE Börsen-Geflüster

Kurse

187,25
-0,24%
Veeva Systems Inc. Realtime-Chart

To register for Veeva R&D and Quality Summit visit: veeva.com/eu/Summit 
Learn more about Veeva Development Cloud: veeva.com/eu/DevelopmentCloud
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/4050205/Veeva_Systems_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-connect-at-veeva-rd-and-quality-summit-to-advance-innovation-for-the-industry-and-patients-301833114.html

Werbung

Mehr Nachrichten zur Veeva Systems Inc. Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News